Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis

BACKGROUND: Risankizumab has demonstrated efficacy and safety in patients with moderate‐to‐severe plaque psoriasis in randomized clinical trials. OBJECTIVES: To evaluate safety data from risankizumab psoriasis phase I–III clinical trials. METHODS: Short‐term safety (through week 16) was analysed usi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gordon, K.B., Lebwohl, M., Papp, K.A., Bachelez, H., Wu, J.J., Langley, R.G., Blauvelt, A., Kaplan, B., Shah, M., Zhao, Y., Sinvhal, R., Reich, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298814/
https://www.ncbi.nlm.nih.gov/pubmed/34652810
http://dx.doi.org/10.1111/bjd.20818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298814/
https://www.ncbi.nlm.nih.gov/pubmed/34652810
http://dx.doi.org/10.1111/bjd.20818

Ejemplares similares